Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

Main conclusionsObjectiveFurther improvehealth forpatients andsociety11Diabetes is a is challenging a challenging disease disease for patients, for patients, and a major and and a major underestimated and source ofmedical underestimated costs and lost source productivity of medical for society costs and lost productivity for society• 1.0-1.1M 1.0-1.1M diabetes diabetes patients patients (~100,000 (~100,000 more diagnosed more diagnosed patients patients than reported) than reported)• EUR 4-5 EUR B total 4 -5 medical B total costs medical for costs diabetes for diabetes patients, patients, of which of EUR which 2.5 EUR B costs 2.5 for B costs diabetestreatment for and diabetes complications treatment (more and complications than double of (more reported). than On double top of that reported). EUR 6 On B lost topproductivity of that EUR 6 B lost productivity• Total costs Total could costs rise could to EUR rise 16-19 to EUR B 16 in 2020 -19 B in 2020• Diabetes care in The Netherlands has reached a high level of quality, but22Diabetes care in The Netherlands has reached a high level of quality, but there is stillopportunity there is still for further opportunity improvement for further improvementFurther improving health of diabetes patients may lead to EUR 1.5 -2 B ofeconomic benefits in 2020 (less medical costs and higher productivity)33Further improving health of diabetes patients may lead to EUR 1.5-2 B of economic benefits in2020 (less medical costs and higher productivity)Insurers and governments should adjust certain economic incentives to11 Refine stimulate economic high incentives quality to care encourage integrated care and quality improvementThe roadFewer barriersfor quality in ourhealth caresystemTo increase labour participation, government and companies can invest indiabetes care via collective insurance models22Engage employers, UWV and participative care in diabetes care3 Engage the patient’s social network to support self managementInsurers , patient federations and Pharma companies could facilitate34 Introduce conditional market access models for new therapies and medication to assessnetwork solutions around the patient to support better diabetes carebehavioural impact4Government and insurers could introduce temporary medication marketaccess models to assess impact on therapy complianceBooz & Company 14 November 201110Prepared for Novo Nordisk2
11Diabetes is a major and underestimated source of medical costsDiabetes is major and underestimated source ofand medical lost costs productivity and lost productivityMore than 1M diabetes patients in the Netherlands2010; ‘000Diabetes Type 1 may be more prevalent than assumed2010; ‘000Higherprevalence~710-850~920-975~95-190~1,0 M-1.1 M75-90~100--125More costsDiagnosedother sources1)DiagnosedBooz estimateUndiagnosed2)TotalTraditional estimateBooz estimateCosts of complications and treatment diabetes double of reported. Lost productivity more than medical costsEUR B , 20101.21.3X22-31.84-5>X25-610-1158%42%Type 2Type 1Reportedmedical costs (RIVM)Unreportedcost of complications~1.4 M Diabetes Patients in 2020MCosts diabetestreatment andcomplicationsOther medical costsfor diabetes patientsTotal medical costsfor diabetes patientsLost productivitydisabledMedical andproductivity costsdiabetes patientsTotal costs could rise to EUR 16-19 BEUR BFaster growth1.0-1.1+3%1.3-1.5Cost grow faster due toincreasing share ofdiabetes patients inworkforce age10-11+5%16-1920102020201020201) Other sources include CBS (710), DVN (750) and RIVM (850) (2) Range between 10% and 20%Source: CBS, DVN, RIVM, SFK, Janssen et al. Screening Study, DFN, IDF, CMR-Nijmegen, ADA, Diabetes Richtlijnen, DBC pricelist 2011, DiabetesZorgBeter, UWV, Booz & Company AnalysisBooz & Company 14 November 2011Prepared for Novo Nordisk411
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11: ContentsSummarized findings and rec
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 33 and 34: ContentsSummarized findings and rec
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63:
But new medication could add a lot
Page 64 and 65:
ContentsSummarized findings and rec
Page 66:
Booz & Company is a global manageme
show all

Diabetes Care in The Netherlands: - Novo Nordisk

Create successful ePaper yourself

Delete template?

Save as template?